Literature DB >> 24798830

Point: were industry-sponsored roflumilast trials appropriate? Yes.

Samy Suissa, Klaus F Rabe.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24798830     DOI: 10.1378/chest.14-0112

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  2 in total

1.  Response.

Authors:  Jason Rho; Nancy Ho; Vinay Prasad
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

2.  Rebuttal from Dr Rho et al.

Authors:  Jason Rho; Nancy Ho; Vinay Prasad
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.